Table 3.
Clinical and biological characteristics of CARV episodes in allo‐HSCT recipients according to the development of a later invasive pulmonary infectious disease
| CARV Without IFD (n = 568) | CARV With IFD (n = 29) | P value | |
|---|---|---|---|
| Immunodeficiency Scoring Index, n (%)a | |||
| ANC < 0.5 × 109/L (3pts) | 42 (7) | 5 (17) | .07 |
| ALC< 0.2 × 109/L (3pts) | 72 (13) | 10 (34) | .003 |
| Age ≥ 40 y (2pts) | 401 (71) | 23 (79) | .6 |
| Myeloablative conditioning regimen (1pt) | 284 (50) | 17 (59) | .4 |
| GvHD (acute or chronic; 1pt) | 287 (51) | 20 (69) | .05 |
| Corticosteroids (1pt) | 190 (33) | 20 (69) | .0001 |
| Recent or pre‐engraftment allo‐HSCT (1pt) | 54 (10) | 4 (14) | .5 |
| ISI, n (%) | |||
| Low risk (0‐2) | 198 (35) | 2 (7) | |
| Moderate risk (3‐6) | 308 (54) | 21 (72) | .005 |
| High risk (7‐12) | 61 (11) | 6 (21) | |
| Other characteristicsa | |||
| On IS, n (%) | 426 (75) | 26 (90) | .07 |
| ALC< 0.1 × 109/L, n (%) | 48 (8) | 4 (14) | .23 |
| ALC < 0.5 × 109/L, n (%) | 135 (23) | 15 (52) | .002 |
| Allo‐HSCT ≤ 6 mo, n (%) | 197 (35) | 15 (52) | .07 |
| Allo‐HSCT ≤ 1 y, n (%) | 337 (59) | 26 (90) | .0001 |
| IFD prophylaxis during CARV infection, n (%) | |||
| Triazole | 159 (28) | 15 (52) | .001 |
| No prophylaxis | 409 (73) | 14 (48) | |
| CARV characteristics and clinical consequences | |||
| CARV LRTD, n (%) | 178 (31) | 25 (86) | .0001 |
| Possible | 95 (16) | 11 (38) | .5 |
| Proven | 83 (14) | 14 (48) | .5 |
| Hospital admission, n (%) | 171 (30) | 23 (79) | .0001 |
| Fever during CARV, n (%) | 320 (57) | 23 (79) | .005 |
| Overall mortality rate, n (%) | 92 (16) | 17 (58) | .0001 |
| Day + 30 | 15 (3) | 3 (10) | .05 |
| Day + 60 | 23 (5) | 6 (21) | .002 |
| Day + 90 | 36 (6) | 6 (21) | .01 |
Abbreviations: ALC, absolute lymphocyte count; Allo‐HSCT, allogeneic hematopoietic stem cell transplantation; ANC, absolute neutrophil count; ATG, antithymocyte globulin; CARV, community‐acquired respiratory virus; GvHD, graft‐versus‐host disease; IFD, invasive pulmonary infectious fungal disease; IS, immunosuppressants; LRTD, lower respiratory tract disease.
All variables were captured at the time of CARV diagnosis.
This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.